Bladder cancer:
a growing global challenge
This content is for informational purposes only and is not intended as medical advice.
Bladder cancer is one of the most prevalent cancers in the world today
9th
most common cancer worldwide1
>600,000
new cases diagnosed in 2022**1
~75%
of bladder cancers diagnosed are superficial tumours2
Bladder cancer is among the most expensive cancers to treat3
Superficial bladder cancer care presents ongoing clinical challenges
While superficial bladder cancer usually comes with a low mortality risk,4 the current treatment pathway relies on OR-based surgical procedures under general anaesthesia, such as transurethral resection of bladder tumours (TURBT).
The current reliance on OR-based procedures creates strain for patients and health systems alike.
On top of this, recurrence and comorbidities can amplify the treatment burden for patients, and elevate risk of complications.
~50-70%
recurrence rate in patients with superficial bladder cancer after initial treatment2
Up to 50%
of OR capacity occupied by bladder cancer cases on urology wards5
Pioneering assistive laser technology to redefine bladder cancer management
Optheras was founded by specialists from the largest urology department in Northern Europe and experienced laser industry professionals, with a shared mission: to create an innovative laser platform to unlock superficial bladder cancer treatment outside of the OR.